|Bid||6.45 x 0|
|Ask||6.70 x 0|
|Day's Range||6.55 - 6.55|
|52 Week Range||3.20 - 9.25|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 06, 2023 - Mar 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.71|
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...